Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
Abstract Medulloblastoma is the most common high-grade brain tumor in childhood. Medulloblastomas with c-myc amplification, classified as group 3, are the most aggressive among the four disease subtypes resulting in a 5-year overall survival of just above 50%. Despite current intensive therapy regim...
Guardado en:
Autores principales: | Stefanie Schwinn, Zeinab Mokhtari, Sina Thusek, Theresa Schneider, Anna-Leena Sirén, Nicola Tiemeyer, Ignazio Caruana, Evelina Miele, Paul G. Schlegel, Andreas Beilhack, Matthias Wölfl |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d110698f9bd945e084481c034902c1df |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
por: Evan F. Garner, et al.
Publicado: (2018) -
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
por: Pratiti Bandopadhayay, et al.
Publicado: (2019) -
Modeling medulloblastoma in vivo and with human cerebellar organoids
por: Claudio Ballabio, et al.
Publicado: (2020) -
Tuning gut microbiota through a probiotic blend in gemcitabine‐treated pancreatic cancer xenografted mice
por: Concetta Panebianco, et al.
Publicado: (2021) -
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari J, et al.
Publicado: (2013)